Novo Nordisk lowered its full-year profit forecast on Wednesday, marking an early challenge for newly appointed CEO Mike Doustdar as the Danish drugmaker grapples with slowing sales and a fast-changing obesity drug market.The maker of Wegovy, once Europe’s most valuable company, said it now expects operating profit growth in local…
Everyone says we’re in an AI bubble. CEOs say it. Economists say it. Retail investors say it on social…
Yum Brands says it is exploring strategic options for Pizza Hut, a review that could include a potential sale…
S&P 500, Nasdaq futures slipped on Wednesday, as the broader market continued to pull back. The difference mostly comes down…
After a year of contraction, the UK’s manufacturing sector has shown a strong recovery, driven by the phased restart…
The Trump administration informed a Rhode Island federal judge on Monday that it would draw on contingency funds to…
The ASX 200 Index continued its downtrend as Australian bond yields jumped after the Reserve Bank of Australia (RBA)…
Global attention was fixed on a range of significant developments this past week, from a major policy speech in…
Australian households, including those without rooftop solar, are set to receive at least three hours of free solar power…